Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2)

Objective: To determine the frequency and relative importance of the most life-affecting symptoms in myotonic dystrophy type 2 (DM2) and to identify the factors that have the strongest association with these symptoms. Methods: We conducted a cross-sectional study of adult patients with DM2 from a National Registry of DM2 Patients to assess the prevalence and relative importance of 310 symptoms and 21 symptomatic themes. Participant responses were compared by age categories, sex, educational attainment, employment status, and duration of symptoms. Results: The symptomatic themes with the highest prevalence in DM2 were the inability to do activities (94.4%), limitations with mobility or walking (89.2%), hip, thigh, or knee weakness (89.2%), fatigue (89.2%), and myotonia (82.6%). Participants identified the inability to do activities and fatigue as the symptomatic themes that have the greatest overall effect on their lives. Unemployment, a longer duration of symptoms, and less education were associated with a higher average prevalence of all symptomatic themes (p < 0.01). Unemployment, a longer duration of symptoms, sex, and increased age were associated with a higher average effect of all symptomatic themes among patients with DM2 (p < 0.01). Conclusions: The lives of patients with DM2 are affected by a variety of symptoms. These symptoms have different levels of significance and prevalence in this population and vary across DM2 subgroups in different demographic categories.

[1]  Hilla Peretz,et al.  Ju n 20 03 Schrödinger ’ s Cat : The rules of engagement , 2003 .

[2]  S. Naylor,et al.  Myotonic Dystrophy Type 2 Caused by a CCTG Expansion in Intron 1 of ZNF9 , 2001, Science.

[3]  G. Beilman,et al.  Myotonic dystrophy type 2 , 2003, Neurology.

[4]  A. Roalfe,et al.  Prevalence of irritable bowel syndrome: a community survey. , 2004, The British journal of general practice : the journal of the Royal College of General Practitioners.

[5]  R. Abresch,et al.  The reliability and validity of a self-report version of the FIM instrument in persons with neuromuscular disease and chronic pain. , 2005, Archives of physical medicine and rehabilitation.

[6]  G. Meola,et al.  140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management , 2006, Neuromuscular Disorders.

[7]  B. Leplow,et al.  Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2) , 2006, Neurology.

[8]  G. Meola,et al.  Cerebral involvement in myotonic dystrophies , 2007, Muscle & nerve.

[9]  R. Abresch,et al.  Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy. , 2008, Archives of physical medicine and rehabilitation.

[10]  K. Raichle,et al.  Impact of Biopsychosocial Factors on Chronic Pain in Persons With Myotonic and Facioscapulohumeral Muscular Dystrophy , 2009, The American journal of hospice & palliative care.

[11]  G. Bleijenberg,et al.  Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2 , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  M. Tittgemeyer,et al.  The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease , 2011, Brain : a journal of neurology.

[13]  R. Moxley,et al.  Laboratory abnormalities in patients with myotonic dystrophy type 2. , 2011, Archives of neurology.

[14]  E. S. St. Louis,et al.  Sleep Disturbances in Myotonic Dystrophy Type 2 , 2012, European Neurology.

[15]  R. Tawil,et al.  Patient‐identified disease burden in facioscapulohumeral muscular dystrophy , 2012, Muscle & nerve.

[16]  R. Moxley,et al.  Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1) , 2012, Neurology.

[17]  C. Heatwole,et al.  Myotonic Dystrophy: From Bench to Bedside , 2012, Seminars in Neurology.

[18]  S. Chokroverty,et al.  REM behavior disorder in myotonic dystrophy type 2 , 2012, Neurology.

[19]  S. Chokroverty,et al.  Sleep disordered breathing and other sleep dysfunction in myotonic dystrophy type 2. , 2012, Sleep medicine.

[20]  K. Raichle,et al.  Changes in Pain-related Beliefs, Coping, and Catastrophizing Predict Changes in Pain Intensity, Pain Interference, and Psychological Functioning in Individuals With Myotonic Muscular Dystrophy and Facioscapulohumeral Dystrophy , 2012, The Clinical journal of pain.

[21]  R. Moxley,et al.  If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). , 2012, Contemporary clinical trials.

[22]  H. Kautiainen,et al.  Pain in patients with myotonic dystrophy type 2: A postal survey in finland , 2012, Muscle & nerve.

[23]  Muscle force development after low‐frequency magnetic burst stimulation in dogs , 2012, Muscle & nerve.

[24]  C. E. Pearson,et al.  Illuminating CNS and cognitive issues in myotonic dystrophy: Workshop report , 2013, Neuromuscular Disorders.

[25]  R. Moxley,et al.  Diagnostic odyssey of patients with myotonic dystrophy , 2013, Journal of Neurology.

[26]  B. Boeve,et al.  Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2 , 2013, Neurology.

[27]  G. Meola,et al.  Consensus on cerebral involvement in myotonic dystrophy Workshop report: May 24–27, 2013, Ferrere (AT), Italy , 2014, Neuromuscular Disorders.

[28]  N. Mercuri,et al.  Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and self‐reported questionnaires , 2014, European journal of neurology.

[29]  J. Miró,et al.  Pain location and intensity impacts function in persons with myotonic dystrophy type 1 and facioscapulohumeral dystrophy with chronic pain , 2014, Muscle & nerve.